Precision Oncology Comes of Age: Tumor-Agnostic Approaches

Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Lewis, Colleen, Harvey, R. Donald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2020
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7857330/
https://www.ncbi.nlm.nih.gov/pubmed/33598315
http://dx.doi.org/10.6004/jadpro.2020.11.3.2
Descripción
Sumario:Colleen Lewis, MSN, ANP-BC, AOCNP®, and R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, presented on the new world of tumor-agnostic treatment approaches, including those aimed at managing patients with tumors that have high microsatellite instability (MSI-H) or neurotrophic receptor tyrosine kinase (NTRK) fusions. Learn about the clinical trial designs that enable development of these novel therapies, and discover how testing methodologies support precision medicine advances.

Ejemplares similares